The membrane proteinase 3 expression on neutrophils was downregulated after treatment with infliximab in patients with rheumatoid arthritis.
Proteinase 3 (PR3) expression on neutrophils was examined in rheumatoid arthritis (RA) patients before and after antitumor necrosis factor (TNF)-alpha therapy. Membrane PR3 expression from patients with either an infection or RA significantly increased. Membrane PR3 expression on neutrophils from RA patients treated with infliximab (anti-TNF-alpha antibody) therapy was less than in those without such treatment in a resting state, but the expression later increased after stimulation in vitro. Membrane PR3 expression increased because of the stimulation of TNFalpha, whereas it was significantly suppressed by plasma or alpha(1)-proteinase inhibitor. The condition of patients with RA improved after treatment with infliximab. Membrane PR3 expression on neutrophils in RA patients was downregulated by infliximab. As a result, PR3 might play an important role in the neutrophil-mediated inflammatory reaction in patients with either RA or an infection.
Matsumoto
Takeshi
T
Department of Hematology and Oncology, Patient Safety Division, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, Japan.
Kaneko
Toshihiro
T
Seto
Masashi
M
Wada
Hideo
H
Kobayashi
Toshihiko
T
Nakatani
Kaname
K
Tonomura
Harue
H
Tono
Yasutaka
Y
Ohyabu
Mariko
M
Nobori
Tsutomu
T
Shiku
Hiroshi
H
Sudo
Akihiro
A
Uchida
Atsumasa
A
Kurosawa
Deborah J Stearns
DJ
Kurosawa
Shinichiro
S
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000201:enzymology; D002462:Cell Membrane / Q000201:enzymology; D015536:Down-Regulation; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D053146:Myeloblastin / Q000032:analysis* / Q000037:antagonists & inhibitors; D009504:Neutrophils / Q000201:enzymology*; D011480:Protease Inhibitors / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D011480:Protease Inhibitors; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D053146:Myeloblastin